EHA 2025: Surovatamig shows promise, but needs to outperform established therapi...
Shares in both companies were down following news of the second death, casting f...
Ethris has entered a strategic partnership with Thermo Fisher Scientific for pro...
NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep...
NextCure has entered a strategic partnership with Simcere Zaiming, to develop SI...
After Biogen failed with a takeover bid in January, Supernus has swooped in to b...
MSD has received US Food and Drug Administration (FDA) approval for its anti-pro...
AstraZeneca is the latest pharma company enlisting the services of Chinese biote...
Late-stage pipeline products can generate demand in the MG market and with diagn...
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biot...
The label expansion for Moderna’s jab arrives at a juncture in America’s changin...
Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explo...
The health secretary addressed NHS employees a day after the £29bn NHS funding w...
The future of US immunisation is up in the air as outspoken critics of vaccines ...
GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will cha...
